Abstract：
OBJECTIVE: This paper was aimed at unveiling the effect of low-molecular-weight heparin calcium (LMWH) combined with magnesium sulfate and labetalol on coagulation, vascular endothelial function, and pregnancy outcome in early-onset severe preeclampsia (EOSP).
METHODS: Pregnant women with EOSP were divided into the control group and the study group, each with 62 cases. Patients in the control group were treated with labetalol and magnesium sulfate, and those in the study group were treated with LMWH in combination with the control grou Blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), 24-h urine protein, coagulation indices [D-dimer (D-D), plasma fibrinogen (Fg), prothrombin time (PT), activated partial thromboplastin time (APTT), and prothrombin time (TT)], endothelial function [endothelin (ET-1) and nitric oxide (NO)], oxidative stress indices [oxidized low-density lipoproteins (ox-LDL), lipid peroxidation (LPO), superoxide dismutase (SOD), and malondialdehyde (MDA)], pregnancy outcome, and adverse effects occurred in the two groups were compared.
RESULTS: After treatment, lower SBP, DBP, and 24-h urine protein levels; lower Fg and D-D levels; higher PT, APPT, and TT levels; higher NO levels; lower ET-1 levels; lower ox-LDL, MDA, and LPO levels; higher SOD levels; and lower incidence of adverse pregnancy and adverse reactions were noted in the study group in contrast to the control group.
CONCLUSIONS: EOSP patients given with LMWH combined with magnesium sulfate and labetalol can effectively reduce the patient\'s blood pressure and urinary protein level; improve coagulation function, oxidative stress, and vascular endothelial function indices; reduce the adverse pregnancy outcomes; and improve the safety of treatment.
METHODS: Pregnant women with EOSP were divided into the control group and the study group, each with 62 cases. Patients in the control group were treated with labetalol and magnesium sulfate, and those in the study group were treated with LMWH in combination with the control grou Blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]), 24-h urine protein, coagulation indices [D-dimer (D-D), plasma fibrinogen (Fg), prothrombin time (PT), activated partial thromboplastin time (APTT), and prothrombin time (TT)], endothelial function [endothelin (ET-1) and nitric oxide (NO)], oxidative stress indices [oxidized low-density lipoproteins (ox-LDL), lipid peroxidation (LPO), superoxide dismutase (SOD), and malondialdehyde (MDA)], pregnancy outcome, and adverse effects occurred in the two groups were compared.
RESULTS: After treatment, lower SBP, DBP, and 24-h urine protein levels; lower Fg and D-D levels; higher PT, APPT, and TT levels; higher NO levels; lower ET-1 levels; lower ox-LDL, MDA, and LPO levels; higher SOD levels; and lower incidence of adverse pregnancy and adverse reactions were noted in the study group in contrast to the control group.
CONCLUSIONS: EOSP patients given with LMWH combined with magnesium sulfate and labetalol can effectively reduce the patient\'s blood pressure and urinary protein level; improve coagulation function, oxidative stress, and vascular endothelial function indices; reduce the adverse pregnancy outcomes; and improve the safety of treatment.
摘要：
目的：本文旨在揭示低分子肝素钙（LMWH）联合硫酸镁和拉贝洛尔对凝血功能的影响。血管内皮功能,早发型重度子痫前期（EOSP）的妊娠结局。
方法：将妊娠合并EOSP的孕妇分为对照组和研究组,各62例。对照组患者给予拉贝洛尔和硫酸镁治疗,研究组采用LMWH联合对照组治疗血压（收缩压[SBP]和舒张压[DBP]），24小时尿蛋白，凝血指标[D-二聚体（D-D），血浆纤维蛋白原（Fg），凝血酶原时间（PT），活化部分凝血活酶时间（APTT），和凝血酶原时间（TT）]，内皮功能[内皮素（ET-1）和一氧化氮（NO）]，氧化应激指标[氧化低密度脂蛋白（ox-LDL），脂质过氧化（LPO），超氧化物歧化酶（SOD），和丙二醛（MDA）]，妊娠结局,比较两组不良反应发生情况。
结果：治疗后，降低SBP,DBP,和24小时尿蛋白水平；较低的Fg和D-D水平；较高的PT，APPT,和TT水平；较高的NO水平；较低的ET-1水平；较低的ox-LDL，MDA,与对照组相比，研究组和LPO水平较高；SOD水平较高；不良妊娠和不良反应发生率较低。
结论：EOSP患者给予LMWH联合硫酸镁和拉贝洛尔可有效降低患者的血压和尿蛋白水平，改善凝血功能，氧化应激，降低不良妊娠结局,提高治疗安全性。
方法：将妊娠合并EOSP的孕妇分为对照组和研究组,各62例。对照组患者给予拉贝洛尔和硫酸镁治疗,研究组采用LMWH联合对照组治疗血压（收缩压[SBP]和舒张压[DBP]），24小时尿蛋白，凝血指标[D-二聚体（D-D），血浆纤维蛋白原（Fg），凝血酶原时间（PT），活化部分凝血活酶时间（APTT），和凝血酶原时间（TT）]，内皮功能[内皮素（ET-1）和一氧化氮（NO）]，氧化应激指标[氧化低密度脂蛋白（ox-LDL），脂质过氧化（LPO），超氧化物歧化酶（SOD），和丙二醛（MDA）]，妊娠结局,比较两组不良反应发生情况。
结果：治疗后，降低SBP,DBP,和24小时尿蛋白水平；较低的Fg和D-D水平；较高的PT，APPT,和TT水平；较高的NO水平；较低的ET-1水平；较低的ox-LDL，MDA,与对照组相比，研究组和LPO水平较高；SOD水平较高；不良妊娠和不良反应发生率较低。
结论：EOSP患者给予LMWH联合硫酸镁和拉贝洛尔可有效降低患者的血压和尿蛋白水平，改善凝血功能，氧化应激，降低不良妊娠结局,提高治疗安全性。
